Eli Lilly and Co (WBO:LLYC) Net Interest Margin (Bank Only) %


WBO:LLYC Eli Lilly and Co WBO:LLYC
87 GF Score
Price €1,044.00
GF Value €1,218.12
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

WBO:LLYC
87GF Score
Eli Lilly and Co WBO:LLYC
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (WBO:LLYC) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,044.00 is trading 14.3% below its estimated GF Value™ of €1,218.12. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for WBO:LLYC:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €1,218.12 vs. price of €1,044.00 (14.3% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the WBO:LLYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
87GF Score

Get the complete analysis for WBO:LLYC

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,044.00
Price
€1,218.12
GF Value